Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy

被引:67
作者
Lindsey, Jane C.
Malee, Kathleen M.
Brouwers, Pim
Hughes, Michael D.
机构
[1] Northwestern Univ, Chicago Childrens Mem Hosp, Chicago, IL 60614 USA
[2] Harvard Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA
[3] NIMH, Ctr Mental Hlth Res AIDS, NIH, Rockville, MD 20857 USA
关键词
HIV; neurodevelopmental functioning; cohort study; COGNITIVE-DEVELOPMENT; COMBINATION THERAPY; CEREBROSPINAL-FLUID; DEMENTIA COMPLEX; ENCEPHALOPATHY; AIDS; ZIDOVUDINE; MORTALITY; REPLICATION; COMPETENT;
D O I
10.1542/peds.2006-1145
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVES. The purpose of this work was to examine the effects of HIV infection and the impact of highly active antiretroviral treatment with protease inhibitors on neurodevelopmental functioning during the first 3 years of life. PATIENTS AND METHODS. Pediatric AIDS Clinical Trials Group 219/219C is a longitudinal cohort study that has enrolled HIV- infected ( HIV+) and HIV-exposed but uninfected (HIV-) infants and children since 1993. Longitudinal profiles of neurodevelopmental functioning as measured by the Bayley Scales of Infant Development were compared by HIV- infection status before and after the availability of highly active antiretroviral therapy with a protease inhibitor and within infants with Bayley tests available before and after initiating protease inhibitor therapy. RESULTS. In the pre-protease inhibitor era, mean mental and motor scores in HIV+ ( n = 54) infants < 1 year of age were significantly lower than those among HIV- infants ( n = 221) and remained lower up to 2 years of age. After protease inhibitors became available, mean mental and motor functioning of HIV+ infants ( n = 91) < 1 year of age were still significantly lower than those of HIV- infants ( n = 838). However, against a background of declining scores among the HIV- infants, there was evidence of limited improvement in the HIV+ infants relative to their uninfected peers. Among infants who had Bayley II evaluations before and after starting a protease inhibitor, there was a trend to improved mental and motor scores after initiation of protease inhibitor therapy. CONCLUSIONS. The suppression of systemic viral replication and subsequent substantial improvements in survival and immunologic status brought about by highly active antiretroviral therapy have been followed by limited improvements in neurodevelopmental functioning in young children. Additional longitudinal research is needed to better understand the role of antiretroviral therapy as well as the impact of genetic and environmental factors on neurodevelopmental functioning in children affected by HIV.
引用
收藏
页码:E681 / E693
页数:13
相关论文
共 44 条
[1]   HIV-1-associated dementia: A metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes [J].
Anderson, E ;
Zink, W ;
Xiong, HG ;
Gendelman, HE .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S43-S54
[2]   Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex [J].
Aweeka, F ;
Jayewardene, A ;
Staprans, S ;
Bellibas, SE ;
Kearney, B ;
Lizak, P ;
Novakovic-Agopian, T ;
Price, RW .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (01) :39-43
[3]  
Bayley N., 1969, BAYLEY SCALES INFANT
[4]   PEDIATRIC ACQUIRED IMMUNODEFICIENCY SYNDROME - NEUROLOGIC SYNDROMES [J].
BELMAN, AL ;
DIAMOND, G ;
DICKSON, D ;
HOROUPIAN, D ;
LLENA, J ;
LANTOS, G ;
RUBINSTEIN, A .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1988, 142 (01) :29-35
[5]   Child-care effect sizes for the NICHD Study of Early Child Care and Youth Development [J].
Belsky, J ;
Booth-LaForce, CL ;
Bradley, R ;
Brownell, CA ;
Burchinal, M ;
Campbell, SB ;
Clarke-Stewart, KA ;
Cox, M ;
Friedman, SL ;
Huston, A ;
Kelly, JF ;
Knoke, B ;
McCartney, K ;
O'Brien, M ;
Owen, MT ;
Pianta, R ;
Spieker, S ;
Vandell, DL ;
Weinraub, M .
AMERICAN PSYCHOLOGIST, 2006, 61 (02) :99-116
[6]   Morbidity and mortality in European children vertically infected by HIV-1 - The French pediatric HIV infection study group and European collaborative study [J].
Blanche, S ;
Newell, ML ;
Mayaux, MJ ;
Dunn, DT ;
Teglas, JP ;
Rouzioux, C ;
Peckham, CS .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 14 (05) :442-450
[7]   Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children [J].
Buchacz, K ;
Cervia, JS ;
Lindsey, JC ;
Hughes, MD ;
Seage, GR ;
Dankner, WM ;
Oleske, JM ;
Moye, J .
PEDIATRICS, 2001, 108 (04) :E72
[8]   Cumulative risk and early cognitive development: A comparison of statistical risk models [J].
Burchinal, MR ;
Roberts, JE ;
Hooper, S ;
Zeisel, SA .
DEVELOPMENTAL PSYCHOLOGY, 2000, 36 (06) :793-807
[9]   Early cognitive and motor development among infants born to women infected with human immunodeficiency virus [J].
Chase, C ;
Ware, J ;
Hittelman, J ;
Blasini, I ;
Smith, R ;
Llorente, A ;
Anisfeld, E ;
Diaz, C ;
Fowler, MG ;
Moye, J ;
Kaligh, LI .
PEDIATRICS, 2000, 106 (02)
[10]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180